EDGAR Filing Documents for 0001193125-24-067984

Form POSASR - Post-effective Amendment to an automatic shelf registration statement:

SEC Accession No. 0001193125-24-067984

Filing Date

2024-03-14

Accepted

2024-03-14 16:51:30

Documents

Effectiveness Date

2024-03-14

Document Format Files

Seq	Description	Document	Type	Size
1	POSASR	d807836dposasr.htm	POSASR	404340
2	EX-5.1	d807836dex51.htm	EX-5.1	26683
3	EX-23.1	d807836dex231.htm	EX-23.1	2291
4	EX-FILING FEES	d807836dexfilingfees.htm	EX-FILING FEES	61417
5	GRAPHIC	g807836dsp1.jpg	GRAPHIC	8886
6	GRAPHIC	g807836g00a01.jpg	GRAPHIC	46892
	Complete submission text file	0001193125-24-067984.txt		568742

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080

Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700

Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: POSASR | Act: 33 | File No.: 333-268117 | Film No.: 24751003
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)